St. Jude announces breakthrough in eye cancer treatment
Researchers use new, localized treatment to shrink retinoblastoma tumors, avoid chemo; treatment could be effective against some breast, lung, prostate and colon cancers
Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy. The treatment also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.
A report on this work appears in the Nov. 2 issue of the journal Nature.
Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. The cancer is fatal if left untreated.
The new treatment holds promise for a simpler, more effective and less-toxic treatment for retinoblastoma that would eliminate the need for the current, complex therapy, according to senior author Michael Dyer, Ph.D., a Pew Scholar and associate member of the St. Jude Department of Developmental Neurobiology. The treatment is based on a discovery by Dyer's laboratory that overturned a widely held belief about the process of apoptosis (cell suicide) in retinoblastoma. Apoptosis is the way the body rids itself of abnormal cells that might become cancerous or cause other problems.
Until now, retinoblastoma experts thought that a mechanism called the p53 pathway triggered apoptosis in other types of cancer cells, but not in retinoblastoma. However, the St. Jude team proved not only that the p53 pathway was activated in early-stage retinoblastoma, but that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors. Based on this discovery, the St. Jude team used a molecule called nutlin-3 to block MDMX in retinoblastoma cells in test tube studies as well as in mouse models. The molecule was originally developed by
Roche Pharmaceuticals (Nutley, N.J.) for a similar use against a related target called MDM2 in adult cancer cells. The success in knocking out MDMX with nutlin-3 represents the first example of local delivery of a targeted chemotherapy drug for any childhood cancer, Dyer said.
Targeted therapy uses a customized drug to disable a specific molecule inside a growing cancer cell; local delivery is the placement of a drug at the site of disease, rather than systemic treatment. In systemic treatment, such as chemotherapy, a drug is infused into the body through a vein and then circulates, often causing toxic side effects that are especially challenging in children.
After demonstrating that nutlin-3 is effective when applied directly to the eye, the St. Jude team modified the treatment by combining this molecule with topotecan, a drug also being investigated in the treatment of retinoblastoma. Local delivery of this two-drug targeted treatment was even more effective, reducing tumor size significantly more than the most effective known combination of standard chemotherapy drugs.
"The findings suggest that this treatment not only could offer children with retinoblastoma more effective and less-toxic treatment," Dyer said. "It could also increase the chance that their vision can be preserved by eliminating the tumor and preventing its spread from the eye to the rest of the body."
The discovery that blocking MDMX releases the apoptosis response in retinoblastoma has important implications for certain forms of adult cancers as well. "Some forms of breast, lung, prostate and colon cancer are caused by abnormally large quantities of MDMX in the cells," Dyer explained. "So knocking out MDMX in those cancers might also dramatically reduce tumor size. And administering the drug directly to the site of the tumor could make the treatment especially effective while avoiding the toxicity caused by systemic exposure." This could mean the eventual elimination of all-body chemotherapy for certain cancers.
This work is likely to have its biggest impact on the care of children with retinoblastoma internationally, according to Dyer. Most children in the United States with retinoblastoma do not die from the disease because they benefit from early detection and advanced medical treatment. The complex treatment includes chemotherapy, radiation and laser therapy, as well as control of infections caused by treatment-related suppression of the immune system. However, most of the 5,000 children worldwide who are found to have retinoblastoma live primarily in countries with limited resources and have restricted access to medical treatment, according to Carlos Rodriguez-Galindo, M.D., an associate member of the St. Jude Oncology department.
"Today, those children do not have access to the advanced treatments available in other countries, such as the United States," Rodriguez-Galindo said, "but our new approach has the potential to make the treatment of retinoblastoma simpler and less toxic. Ideally, these treatments could be administered even in countries that cannot afford the highly complex infrastructure now required to manage children with retinoblastoma. This would mean saving many more lives and preserving more vision." Rodriguez-Galindo is a co-author of the paper.
Retinoblastoma can occur as a unilateral (one eye) or bilateral (both eyes) disease. In the case of unilateral disease, surgeons generally remove the eye that has the cancer in order to prevent the disease from spreading. However, children with bilateral retinoblastoma pose a significant challenge to physicians, who are reluctant to remove both eyes from young children, said Matthew Wilson, M.D., a surgeon in the St. Jude ophthalmology division and a co-author of the paper. In those cases, the physicians institute aggressive systemic chemotherapy to reduce the size of the tumor, followed by one of several possible therapies such as radiation or lasers to destroy the remaining cancer cells in the eye. "When successful, this therapy often saves vision," Wilson said. "Clinicians at major medical institutions generally save 70 percent of all eyes treated, even in the case of advanced disease."
Other authors of the paper include Nikia Laurie and Stacy Donovan, co-first authors who contributed equally to this work; Chie-Schin Shih, Jiakun Zhang, Nicholas Mills, Christin Fuller, Adithi Mohan and R. Kiplin Guy (St. Jude); Amina Teunisse, Suzanne Lam, Yolande Ramos and Aart G. Jochemsen (Leiden University Medical Center, the Netherlands); Dianna Johnson (University of Tennessee, Memphis); Micaela Quarto (FIRC Institute of Molecular Oncology, Milan, Italy); Sarah Francoz and Jean-Christophe Marine (Flanders Interuniversity Institute for Biotechnology, Ghent, Belgium); and Susan M. Mendrysa (Purdue University, West Lafayette, Ind.).
This work was supported in part by the National Institutes of Health, Cancer Center Support from the National Cancer Institute, the American Cancer Society, Research to Prevent Blindness, the Pearle Vision Foundation, the International Retinal Research Foundation, the European Community, the Association for International Cancer Research, the Dutch Cancer Society, the Belgian Foundation Against Cancer, TÚlÚvie and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.